 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...2223242526272829303132...123124» |
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal, Real-world evidence, Real-world, Metastases: Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study. (Pubmed Central) - Nov 29, 2023
Monotherapy with TACE, or Lenvatinib, or PD-1 inhibitors has shown limited efficacy over standard first-line chemotherapy in advanced and metastatic ICC. This work suggested the combined potency of these treatments and well-tolerance.
- | Retrospective data, Journal, Metastases: Small molecule multitarget antiangiogenic inhibitor treatments for advanced thymic epithelial tumors: A retrospective study. (Pubmed Central) - Nov 28, 2023
This work suggested the combined potency of these treatments and well-tolerance. The findings suggest that small molecule multitarget antiangiogenic inhibitors are efficacious as second or post-line treatments as a viable alternative treatment option for patients with advanced TETs.
- || PK/PD data, Review, Journal: Pharmacokinetic considerations for angiogenesis inhibitors used to treat hepatocellular carcinoma: an overview. (Pubmed Central) - Nov 28, 2023
Anti-angiogenic drugs have different profiles in terms of bioavailability, metabolism, elimination and interindividual variability in their pharmacokinetics and effectiveness. More studies should be developed to address the intrinsic and extrinsic factors influencing pharmacokinetics parameters to improve the individual therapeutic response and, furthermore, to evaluate the benefit and the harm of systemic therapy for advanced HCC in selected patients with liver impairment.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase classification: Hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and pembrolizumab as neoadjuvant therapy for resectable hepatocellular carcinoma in part BCLC C: a multicenter randomized controlled clinical trial (EUDRACT) - Nov 27, 2023
P2/3, N=118, Not yet recruiting, Sponsor: The Fifth Affiliated Hospital of Sun Yat-Sen University ; The Fifth Affiliated Hospital of Sun Yat-Sen University
More studies should be developed to address the intrinsic and extrinsic factors influencing pharmacokinetics parameters to improve the individual therapeutic response and, furthermore, to evaluate the benefit and the harm of systemic therapy for advanced HCC in selected patients with liver impairment. Phase classification: P=N/A --> P2/3
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2/3 trial: Hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and pembrolizumab as neoadjuvant therapy for resectable hepatocellular carcinoma in part BCLC C: a multicenter randomized controlled clinical trial (EUDRACT) - Nov 27, 2023
P2/3, N=118, Not yet recruiting, Sponsor: The Fifth Affiliated Hospital of Sun Yat-Sen University ; The Fifth Affiliated Hospital of Sun Yat-Sen University
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Adherence: Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma. (Pubmed Central) - Nov 27, 2023
The adherence rate for lenvatinib in Japanese patients with thyroid and hepatocellular carcinoma in real-world clinical practice was more than 90% in this study. Hypertension was a major reason for non-adherence, followed by hand-foot skin reactions and diarrhea.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker: Lenvatinib delivery using a Gd/Fe bimetallic MOF: enhancing antitumor immunity following microwave-based thermal therapy. (Pubmed Central) - Nov 27, 2023
This is significant because MW-induced immune responses are relatively weak and usually fail to effectively prevent tumor recurrence. The combination of MW treatment with an immunomodulatory strategy may solve this problem.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, IO biomarker: Targeting NAD metabolism of hepatocellular carcinoma cells by lenvatinib promotes M2 macrophages reverse polarization, suppressing the HCC progression. (Pubmed Central) - Nov 27, 2023
Targeting HCC cells NAD metabolism by lenvatinib-TET2 pathway drives metabolite crosstalk, leading to M2 macrophages reverse polarization, thereby suppressing HCC progression. Collectively, these novel insights highlight the role of lenvatinib or its combination therapies as promising therapeutic alternatives for HCC patients with low NAD levels or high TET2 levels.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Real-world evidence, Real-world, Metastases: Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population. (Pubmed Central) - Nov 25, 2023
Furthermore, no patients experienced AEs of hematologic toxic effects in the combined therapy group compared with the chemotherapy group, demonstrating the advantage of the combined therapy. Anti-PD-1 antibody combined with lenvatinib may be a potentially effective and tolerable first-line treatment for unresectable stage IV GBC.
- | Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal: Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Nov 25, 2023
There were some frequent adverse events (AEs) in patients treated with lenvatinib such as hypertension, fatigue, anorexia, proteinuria, and so on, but none directly caused death. In conclusion, lenvatinib after atezolizumab plus bevacizumab for unresectable HCC should be considered an effective treatment option.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Prognostic Significance of C-Reactive Protein in Lenvatinib-Treated Unresectable Hepatocellular Carcinoma: A Multi-Institutional Study. (Pubmed Central) - Nov 25, 2023
In conclusion, lenvatinib after atezolizumab plus bevacizumab for unresectable HCC should be considered an effective treatment option. A baseline serum CRP level exceeding 0.5 mg/dL was identified as an unfavorable prognostic factor in HCC patients receiving lenvatinib treatment.
- ||| Retrospective data, Review, Journal, Adverse events: Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis. (Pubmed Central) - Nov 22, 2023
Higher-potency and lower-selectivity VEGF-TKIs may influence the risks of MACEs, heart failure, and thromboembolism. These findings may facilitate evidence-based decision-making in clinical practice.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, PD(L)-1 Biomarker, IO biomarker: Circulating CD8 Lymphocytes Predict Response to Atezolizumab-Bevacizumab in Hepatocellular Carcinoma. (Pubmed Central) - Nov 22, 2023
TRIM56, TRIM16, TRIM64 and Ki67 mRNAs were validated as up-regulated in responders versus non responders after 3 weeks from treatments start, providing a possible evidence of immune activation. Baseline CD8+ and CD8+PD-L1+ peripheral lymphocytes and early changes in CD8+PD1+ lymphocytes predict response to atezolizumab-bevacizumab providing non-invasive markers to complement clinical practice in the very early phases of treatment of HCC patients.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 22, 2023
P2, N=48, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial initiation date: Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma (clinicaltrials.gov) - Nov 22, 2023
P1/2, N=47, Not yet recruiting, Sponsor: Tel Aviv Medical Center
Baseline CD8+ and CD8+PD-L1+ peripheral lymphocytes and early changes in CD8+PD1+ lymphocytes predict response to atezolizumab-bevacizumab providing non-invasive markers to complement clinical practice in the very early phases of treatment of HCC patients. Initiation date: Oct 2023 --> Jan 2024
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1/2 trial, Metastases: The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial. (clinicaltrials.gov) - Nov 21, 2023
P1/2, N=58, Not yet recruiting, Sponsor: Zhejiang Cancer Hospital
- || Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Clinical, Journal: A comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: A multicenter study. (Pubmed Central) - Nov 20, 2023
Atez/Bev showed comparable effectiveness to LEN in HCC patients aged 80 years and older. Given the results of post-progression treatment and discontinuation due to adverse events, Atez/Bev could serve as a first-line treatment even for elderly HCC patients.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: USP22-JMJD8 axis promotes Lenvatinib resistance in hepatocellular carcinoma. (Pubmed Central) - Nov 20, 2023
In the rescue experiment, the overexpression of JMJD8 could reduce the apoptosis induced by USP22 knockdown. In general, this study shows that USP22-JMJD8 is a drug design target for the mechanism of Lenvatinib resistance in HCC, which may improve the long-term efficacy of Lenvatinib.
- || Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
New P2 trial, Metastases: Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 19, 2023
P2, N=50, Recruiting, Sponsor: Asan Medical Center
- | Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Combination therapy: Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC (clinicaltrials.gov) - Nov 18, 2023
P2, N=43, Recruiting, Sponsor: Sun Yat-sen University
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Trial initiation date, Metastases: Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma (clinicaltrials.gov) - Nov 18, 2023
P3, N=80, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
In general, this study shows that USP22-JMJD8 is a drug design target for the mechanism of Lenvatinib resistance in HCC, which may improve the long-term efficacy of Lenvatinib. Not yet recruiting --> Recruiting | Initiation date: Jun 2023 --> Oct 2023
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy, Metastases: Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) (clinicaltrials.gov) - Nov 18, 2023
P2, N=400, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Not yet recruiting --> Recruiting | Initiation date: Jun 2023 --> Oct 2023 Trial completion date: Aug 2024 --> Feb 2027 | Trial primary completion date: Aug 2024 --> Jul 2025
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment change: KEYMAKER-U06 substudy 06B: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (clinicaltrials.gov) - Nov 18, 2023
P1/2, N=200, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Aug 2024 --> Feb 2027 | Trial primary completion date: Aug 2024 --> Jul 2025 N=300 --> 200
- || Review, Journal, Tumor mutational burden, IO biomarker: The Evolving Treatment Landscape of Medullary Thyroid Cancer. (Pubmed Central) - Nov 18, 2023
The best option for subsequent lines is to consider inclusion in clinical trials or alternatively other mTKIs such as sunitinib, sorafenib, lenvatinib, or pazopanib could be evaluated. New perspectives include next-generation RET inhibitors able to overcome resistance mechanisms responsible for disease progression to standard mTKIs and RET inhibitors, and immunotherapy for MTC presenting with high tumor mutational burden.
- | Keytruda (pembrolizumab) / Merck (MSD)
Phase classification: Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) (clinicaltrials.gov) - Nov 18, 2023
P1/2, N=400, Recruiting, Sponsor: Merck Sharp & Dohme LLC
New perspectives include next-generation RET inhibitors able to overcome resistance mechanisms responsible for disease progression to standard mTKIs and RET inhibitors, and immunotherapy for MTC presenting with high tumor mutational burden. Phase classification: P1b/2 --> P1/2
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Synergistic antitumor efficacy of aspirin plus lenvatinib in hepatocellular carcinoma via regulating of diverse signaling pathways. (Pubmed Central) - Nov 17, 2023
Mechanistic studies revealed that aspirin plus lenvatinib could target multiple oncogenes and tumor suppressors, affecting diverse signaling pathways in various biological processes conducive to antitumor effects. Overall, our findings suggest that aspirin plus lenvatinib could serve as a promising combination regimen to improve the therapeutic outcomes of HCC.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Real-world evidence, Real-world: Effectiveness and Safety of the PD-1 Inhibitor Lenvatinib Plus Radiotherapy in Patients with HCC with Main PVTT: Real-World Data from a Tertiary Centre. (Pubmed Central) - Nov 15, 2023
All AEs were controlled, and no treatment-related deaths occurred. Lenvatinib plus PD-1 inhibitor combined with radiotherapy had a significant therapeutic effect and manageable AEs in HCC patients with type Vp-4 PVTT and may be a potential treatment option for advanced HCC.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal, PD(L)-1 Biomarker: Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab. (Pubmed Central) - Nov 15, 2023
3.46 were independent negative factors of PFS. NLR can be associated with outcomes in patients with u-HCC treated with HAIC combined with lenvatinib and camrelizumab.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion: A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC (clinicaltrials.gov) - Nov 14, 2023
P4, N=50, Completed, Sponsor: Eisai Pharmaceuticals India Pvt. Ltd
NLR can be associated with outcomes in patients with u-HCC treated with HAIC combined with lenvatinib and camrelizumab. Recruiting --> Completed
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal, IO biomarker, Pan tumor: Pan-Cancer Analysis and Experimental Validation of SOX4 as a Potential Diagnosis, Prognosis, and Immunotherapy Biomarker. (Pubmed Central) - Nov 14, 2023
Recruiting --> Completed This study highlights that SOX4 may serve as a promising therapeutic target for tumor treatment.
- || Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Clinical, Journal: Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Nov 14, 2023
A comparison of the patients who achieved a partial response with and without conversion was evaluated using propensity score matching to reduce the confounding factors, showing a significant survival benefit in the conversion group (1208 [1064-NA] vs. 665 days, p < 0.01). Among the patients with u-HCC who were treated with LEN and Atezo + Bev, those with mALBI 1 + 2a and BCLC-B were likely to achieve conversion therapy with downstaging.
- || Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
P1/2 data, Journal, Metastases: The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial. (Pubmed Central) - Nov 13, 2023
P1/2
This novel combination therapy showed promising efficacy and manageable toxicity that could provide an option in first-line setting of aHCC. [www.ClinicalTrials.gov], NCT04444167.
- || volrustomig (MEDI5752) / AstraZeneca
Phase classification, Trial completion date, Trial primary completion date: A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Nov 13, 2023
P1, N=179, Recruiting, Sponsor: MedImmune LLC
[www.ClinicalTrials.gov], NCT04444167. Phase classification: P1b --> P1 | Trial completion date: Dec 2025 --> Aug 2027 | Trial primary completion date: Dec 2025 --> Aug 2027
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) (clinicaltrials.gov) - Nov 13, 2023
P3, N=480, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Phase classification: P1b --> P1 | Trial completion date: Dec 2025 --> Aug 2027 | Trial primary completion date: Dec 2025 --> Aug 2027 Trial completion date: Jan 2024 --> Sep 2024
- | Puyouheng (pucotenlimab) / Taizhou Hanzhong Biopharma, Lepu Med, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Nov 12, 2023
P2, N=47, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Combination therapy: Is lenvatinib in combination with transarterial chemoembolization benefit for unresectable hepatocellular carcinoma (uHCC)? The age interference needs to be eliminated. (Pubmed Central) - Nov 9, 2023
Trial completion date: Jan 2024 --> Sep 2024 No abstract available
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Impact of combining Lenvatinib with Transarterial chemoembolization for unresectable hepatocellular carcinoma. (Pubmed Central) - Nov 8, 2023
There were no significant differences in one or two year PFS rate or one year OS between groups (P>0.05), while the two years survival rate in the TACE+lenvatinib group was significantly higher than that in the TACE group (P<0.05). TACE combined with lenvatinib have a high clinical effective rate, with reduced AFP and VEGF levels, higher two year survival rate, and acceptable incidence of adverse events.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors (clinicaltrials.gov) - Nov 7, 2023
P2, N=32, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
TACE combined with lenvatinib have a high clinical effective rate, with reduced AFP and VEGF levels, higher two year survival rate, and acceptable incidence of adverse events. Recruiting --> Active, not recruiting
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Tumor mutational burden: Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma (clinicaltrials.gov) - Nov 7, 2023
P2, N=56, Recruiting, Sponsor: Yale University
Recruiting --> Active, not recruiting Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2026
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data, Journal: Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study. (Pubmed Central) - Nov 6, 2023
P2
This, however, demands a high standard of supportive care. The combination therapy of pembrolizumab and lenvatinib warrants further investigation in pleural mesothelioma.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy. (Pubmed Central) - Nov 6, 2023
This membrane-fusion-participant codelivery strategy optimized the synergetic effect of CRISPR/Cas9 and TKI combinational therapy as indicated by the 0.35 combination index in vitro and the dramatic reduction of subcutaneous and orthotopic TKI-insensitive HCC tumor growth in mice. Therefore, the established LIGHTFUL provides a unique co-delivery platform to combine gene editing and TKI therapies for enhanced synergetic therapy.
- | Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal: Role of organic cation transporter 3 (OCT3) in the response of hepatocellular carcinoma to tyrosine kinase inhibitors. (Pubmed Central) - Nov 6, 2023
Other TKIs, such as regorafenib, lenvatinib, and cabozantinib can also interact with this transporter...In HCC samples, OCT3 was expressed at the PM of cancer cells, and its presence, detected in 26% of tumors, was associated with better outcomes in patients treated with sorafenib. In conclusion, analysis by immunohistochemistry of OCT3 in the PM of tumor cells may help to predict the response of HCC patients to sorafenib and potentially to other TKIs.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: MAIT cells confer resistance to Lenvatinib plus anti-PD1 antibodies in hepatocellular carcinoma through TNF-TNFRSF1B pathway. (Pubmed Central) - Nov 6, 2023
Overall, our findings shed light on the potential mechanisms behind the effectiveness of lenvatinib plus anti-PD1 antibody treatment in HCC patients. By understanding these mechanisms better, we may be able to develop more effective treatment strategies for patients who do not respond to current therapies.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib-Associated Fulminant Type 1 Diabetes Mellitus. (Pubmed Central) - Nov 5, 2023
By understanding these mechanisms better, we may be able to develop more effective treatment strategies for patients who do not respond to current therapies. No abstract available
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal, Monotherapy: A retrospective study of transarterial chemoembolization (TACE) combined with lenvatinib compared with TACE monotherapy for BCLC B2 stage hepatocellular carcinoma. (Pubmed Central) - Nov 5, 2023
Therefore, Len + TACE combination therapy was associated with increased OS and tumor response compared with that of TACE monotherapy in patients with BCLC B2 stage HCC. However, large-scale, multicenter, prospective studies are needed to further confirm these results.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Journal, Real-world evidence, PD(L)-1 Biomarker, IO biomarker, Real-world, Metastases: Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis. (Pubmed Central) - Nov 3, 2023
P=N/A
PD-L1 expression and CA19-9 level appear to predict the treatment efficacy. IDH1 mutations might indicate a better treatment response.
- || Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Retrospective data, Review, Journal: Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. (Pubmed Central) - Nov 3, 2023
Atezolizumab plus bevacizumab provides potential advantage in efficacy and better safety than lenvatinib in the treatment of uHCC. Lenvatinib is an appropriate effective alternative to atezolizumab plus bevacizumab in patients without viral infecting.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, IO biomarker: MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib. (Pubmed Central) - Nov 3, 2023
MEX3C shows promise as a potential therapeutic target for treating HCC. Furthermore, the combination of MEX3C knockdown and Lenvatinib could offer a novel therapeutic avenue for HCC treatment.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Lenvatinib in Locally Advanced Invasive Thyroid Cancer (clinicaltrials.gov) - Nov 3, 2023
P2, N=30, Recruiting, Sponsor: Massachusetts Eye and Ear Infirmary
Furthermore, the combination of MEX3C knockdown and Lenvatinib could offer a novel therapeutic avenue for HCC treatment. Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Sep 2023 --> Dec 2024
- ||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: KEYMAKER-U03B: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B) (clinicaltrials.gov) - Nov 2, 2023
P1b/2, N=370, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Sep 2023 --> Dec 2024 Recruiting --> Active, not recruiting